.png)
Terms of Reference
Aotearoa New Zealand All Cardiology Services Quality Improvement (ANZACS-QI) Data Governance Group document.
Programme Methodology
This information helps to ensure appropriate evidence-based treatment is being received nationwide.
Programme
Methodology
This information helps to ensure appropriate evidence-based treatment is being received nationwide.
Learn about each step of the process
ANZACS-QI is a unique, secure, web-based clinical registry tool that captures data on all cardiac events and cardiology services in Aotearoa New Zealand for the purpose of quality improvement and research.
This information helps to ensure appropriate evidence-based treatment is being received nationwide.
ANZACS-QI's distinctive approach includes a rigorous data auditing process, with national coordinators regularly assessing the accuracy of data collection at hospitals nationwide. This ensures the robustness and reliability of our data, which forms the basis of clinician recommendations and publications aimed at enhancing patient care and outcomes.
This programme has been approved by the NZ Health and Disabilities Ethics committee (MEC07/19/EXP) with annual re-approval).
Registration
Patients are entered into the ANZACS-QI registry when they are admitted to hospital with a cardiological condition.
Data record
The clinical information recorded is available for the clinician providing patient care, to improve patient care quality.
Quality improvement
A de-identified copy of the registry information is linked with routine information that is captured by the Ministry of Health and is used for quality improvement to inform national research.
Data privacy
The ANZACS-QI and VAREANZ Data Governance Groups ensure that patient data housed within the registry is gathered, managed and used appropriately to ensure patient privacy.
Learn about each step of the process
ANZACS-QI's distinctive approach includes a rigorous data auditing process, with national coordinators regularly assessing the accuracy of data collection at hospitals nationwide. This ensures the robustness and reliability of our data, which forms the basis of clinician recommendations and publications aimed at enhancing patient care and outcomes.
This programme has been approved by the NZ Health and Disabilities Ethics committee ((MEC07/19/EXP) with annual re-approval).
Registration
Patients are entered into the ANZACS-QI registry when they are admitted to hospital with a cardiological condition.
Data record
The clinical information recorded is available for the clinician providing patient care, to improve patient care quality.
Quality improvement
A de-identified copy of the registry information is linked with routine information that is captured by the Ministry of Health and is used for quality improvement to inform national research.
Data privacy
The ANZACS-QI and VAREANZ Data Governance Groups ensure that patient data housed within the registry is gathered, managed and used appropriately to ensure patient privacy.
.png)
If you are a Health Professional and would like to gain access to ANZACS-QI data for a clinical trial, please read the DAP Data Access & Publishing Guide and complete the Data Access Proposal Request Form and send it to anzacsqi@nihi.auckland.ac.nz.
What happens in
the registry trials?
What happens in the registry trials?
There are also some separate clinical research studies performed using the registry data but these all required their own ethics approvals.
This data is NHI-encrypted and safely stored in accordance to the ANZACS-QI programme data governance and ethics protocol. The data is then linked to ANZACS-QI and routine information data, and informs the Registry Trials research.
National Indicators for Quality Improvement
ANZACS-QI have set these indicators, which have been endorsed by the National Cardiac Network and the Ministry of Health. They are nationwide key performance indicators (KPIs) for the purpose of quality improvement of cardiac service delivery.
For a complete and detailed description of these indicators, please see
ANZACS-QI National Indicators and Targets May 2024
Acute Coronary Syndrome Clinical Indicators
These indicators capture the three pillars of ACS management - timely intervention, cardiac function assessment, and use of prevention medications.
Door to Cath wait time
Door to Cath within 3 days for ≥ 70% of ACS patients undergoing coronary angiogram.
ACS LVEF assessment
≥85% of ACS patients who undergo coronary angiogram have pre-discharge assessment of Left Ventricular Ejection Fraction (LVEF).
Composite Post ACS Secondary Prevention Medication Indicator
In the absence of a documented contraindication/intolerance ≥ 85% of ACS patients who undergo coronary angiogram should be prescribed guideline medications at discharge.
Vascular Access
≥85% of patients who undergo a coronary angiogram should be studied via the radial artery.
STEMI Symptom Onset to FMC
Symptom onset to first medical contact ≤60 min for STEMI patients. No target is set.
STEMI FMC (ambulance call) to Device
First medical contact (call to ambulance service) to Device (Primary PCI intervention) ≤140 minutes. No target set.
STEMI FMC (ambulance call) to Needle
First medical contact (call to ambulance service) to Needle (Fibrinolysis) ≤60 minutes. No target set.
Cardiac Implantable Device Clinical Indicators
These indicators track the timely implantation of pacemakers (PPMs) and implantable cardiac defibrillators (ICDs).
Pacemaker in-patient wait time
≥ 70% of in-patients referred for a new PPM should be implanted within three days of admission to hospital.
Implantable Cardiac Defibrillator wait time
≥70% of in-patients referred for a new ICD should be implanted within three days of acceptance onto the waitlist.
Registry Data Completion Indicators
ACS Registry completion
≥ 95% of patients presenting with Acute Coronary Syndrome who undergo coronary angiography have completion of ANZACS-QI ACS and Cath/PCI registry data collection within 30 days of discharge and ≥ 99% within three months.
Device Registry completion
≥ 99% of patients who have pacemaker (PPM) or implantable cardiac defibrillator (ICD) implantation/replacement have completion of ANZACS-QI Device PPM and ICD forms within two months of the procedure.
National Indicators for Quality Improvement
ANZACS-QI have set these indicators, which have been endorsed by the National Cardiac Network and the Ministry of Health. They are nationwide key performance indicators (KPIs) for the purpose of quality improvement of cardiac service delivery.
For a complete and detailed description of these indicators, please see ANZACS-QI National Indicators and Targets May 2024
Acute Coronary Syndrome Clinical Indicators
These indicators capture the three pillars of ACS management - timely intervention, cardiac function assessment, and use of prevention medications.
Door to Cath wait time
Door to Cath within 3 days for ≥ 70% of ACS patients undergoing coronary angiogram.
ACS LVEF assessment
≥85% of ACS patients who undergo coronary angiogram have pre-discharge assessment of Left Ventricular Ejection Fraction (LVEF).
Composite Post ACS Secondary Prevention Medication Indicator
In the absence of a documented contraindication/intolerance ≥ 85% of ACS patients who undergo coronary angiogram should be prescribed guideline medications at discharge.
Vascular Access
≥85% of patients who undergo a coronary angiogram should be studied via the radial artery.
STEMI Symptom Onset to FMC
Symptom onset to first medical contact ≤60 min for STEMI patients. No target is set.
STEMI FMC (ambulance call) to Device
First medical contact (call to ambulance service) to Device (Primary PCI intervention) ≤140 minutes. No target set.
STEMI FMC (ambulance call) to Needle
First medical contact (call to ambulance service) to Needle (Fibrinolysis) ≤60 minutes. No target set.
Cardiac Implantable Device Clinical Indicators
These indicators track the timely implantation of pacemakers (PPMs) and implantable cardiac defibrillators (ICDs).
Pacemaker in-patient wait time
≥ 70% of in-patients referred for a new PPM should be implanted within three days of admission to hospital.
Implantable Cardiac Defibrillator wait time
≥70% of in-patients referred for a new ICD should be implanted within three days of acceptance onto the waitlist.
Registry Data Completion Indicators
These indicators track the timely implantation of pacemakers (PPMs) and implantable cardiac defibrillators (ICDs).
ACS Registry completion
≥ 95% of patients presenting with Acute Coronary Syndrome who undergo coronary angiography have completion of ANZACS-QI ACS and Cath/PCI registry data collection within 30 days of discharge and ≥ 99% within three months.
Device Registry completion
≥ 99% of patients who have pacemaker (PPM) or implantable cardiac defibrillator (ICD) implantation/replacement have completion of ANZACS-QI Device PPM and ICD forms within two months of the procedure.
Available Resources
Available Resources
The following documents may be helpful for you:
